Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07205718 · ClinicalTrials.gov registry record · Phase 1

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Takeda.

Recruiting
Registry status
Phase 1
Development phase
223
Enrollment target
15
Study locations

NCT07205718: Recruiting Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Takeda.

NCT07205718 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Takeda. The registered enrollment target is 223 participants, roughly in line with the 225-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target. The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07205718, a Phase 1 study of Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 1
Development phase
223 participants
Enrollment target
15
Study locations

Study Summary

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.

Primary Outcome

An adverse event (AE) is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy.

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • DRUG TAK-188

Study Locations (15)

Texas

  • MD Anderson Cancer Center - Houston
  • NEXT Dallas - Irving
  • START San Antonio - San Antonio

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit
  • START Midwest - Grand Rapids

California

  • UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica) - Santa Monica

Connecticut

  • Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers - New Haven

Florida

  • Florida Cancer Specialists - Lake Nona - Orlando

Maryland

  • Johns Hopkins - Baltimore

Missouri

  • Washington University - St Louis

Ohio

  • Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2025-11-19
Est. Completion 2029-12-21
Phase Phase 1
Takeda

408 total trials

What NCT07205718 shows while recruiting

NCT07205718 is an interventional study that assigns participants to a tested intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 225-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TAK-188 is the first listed.

NCT07205718 lists 15 locations in 12 states (Texas, Michigan, California).

Frequently Asked Questions

What is clinical trial NCT07205718 about?

NCT07205718 is a clinical study titled "A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors". TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cel...

What is the current status of trial NCT07205718?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2025-11-19. Estimated completion is 2029-12-21.

What conditions does trial NCT07205718 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT07205718?

The interventions under investigation include: TAK-188 (DRUG).

Who is sponsoring clinical trial NCT07205718?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07205718 being conducted?

This trial has 15 study locations across California, Connecticut, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07205718's enrollment target sits among peer trials

223 7th of 19 higher than 13 of 19 other Advanced or Metastatic Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced or Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06640803 · 223 participants · NA

    Sacramento Clinical High Risk for Psychosis Stepped-Care Program

  • NCT07175285 · 223 participants

    A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

  • NCT04140344 · 224 participants · NA

    The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07205718

Source: ClinicalTrials.gov NCT07205718, the US trial registry maintained by the National Library of Medicine. NCT07205718 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.